Discovery of PROX1 Gene as an Early Indicator of Aggressive Prostate Cancer
A groundbreaking study by the University of Michigan has identified the PROX1 gene as an early driver of aggressive, treatment-resistant prostate cancer. Targeting PROX1 with existing HDAC inhibitors may offer new therapeutic options for advanced prostate cancer patients.
Researchers at the University of Michigan Rogel Cancer Center have identified a crucial gene, PROX1, that significantly contributes to the progression of prostate cancer toward a more aggressive and treatment-resistant form. This gene plays a key role in the cellular transformation process known as lineage plasticity, which prostate cancer cells undergo to evade traditional therapies targeting the androgen receptor.
Prostate tumors that lose reliance on the androgen receptor — such as double-negative prostate cancer and neuroendocrine prostate cancer — display elevated levels of PROX1. The study found that increased PROX1 expression correlates inversely with androgen receptor activity and may actively regulate its suppression. Experimentally reducing PROX1 levels in aggressive prostate cancer cells led to halted growth and cell death, indicating its potential as a therapeutic target.
Given that PROX1 is a transcription factor—a type of protein traditionally difficult to target directly—researchers explored its associated molecular partners. They discovered that histone deacetylases (HDACs) interact with PROX1. Since HDAC inhibitors are already approved for other cancer treatments and can reduce PROX1 levels, this opens a promising avenue for therapy. When prostate cancer cells expressing PROX1 were treated with HDAC inhibitors, the drug depleted PROX1 and induced tumor cell death, mimicking the effects of genetic PROX1 suppression.
This research suggests that PROX1 is an early driver of prostate cancer's transition to a more aggressive and treatment-resistant state. Using HDAC inhibitors to target this pathway could offer a new treatment strategy for patients with limited options, especially those with advanced, androgen receptor-independent prostate cancers.
The findings were published in the Journal of Clinical Investigation, highlighting the importance of PROX1 in prostate cancer progression and providing insights into potential targeted therapies.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Artificial Intelligence Uncovers Hidden Signs of Parkinson's Disease Through Finger-Tapping Video Analysis
Cutting-edge AI technology analyzes finger-tapping videos to detect early signs of Parkinson's disease, enabling earlier diagnosis and intervention using simple video recordings.
How Colonic Inflammation Links Obesity to β-Cell Growth and Diabetes Development
New research reveals that colon inflammation triggers a liver-pancreas pathway promoting β-cell proliferation, offering insights into obesity-related diabetes development. This discovery highlights potential therapeutic targets for diabetes prevention.
Emerging Evidence Links Carbon Dioxide to Lung Damage in COPD Patients
New studies reveal that high levels of carbon dioxide may actively contribute to lung tissue remodeling and progression of COPD, highlighting the potential for targeted therapies to mitigate disease advancement.
Innovative Algorithm Reveals Links Between Brain Structure and Function
A new algorithm, the Krakencoder, developed by Weill Cornell Medicine researchers, provides a more unified view of how the brain's physical wiring relates to its activity and functions, paving the way for advanced neurological research and treatments.